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Abstract: Aptamers, a group of nucleic acids which can specifically bind to a target molecule, have
drawn extensive interest over the past few decades. For analytics, aptamers represent a viable
alternative to gold-standard antibodies due to their oligonucleic nature combined with advantageous
properties, including higher stability in harsh environments and longer shelf-life. Indeed, over the
last decade, aptamers have been used in numerous bioanalytical assays and in various point-of-care
testing (POCT) platforms. The latter allows for rapid on-site testing and can be performed outside a
laboratory by unskilled labor. Aptamer technology for POCT is not limited just to medical diagnostics;
it can be used for a range of applications, including environmental monitoring and quality control.
In this review, we critically examine the use of aptamers in POCT with an emphasis on their
advantages and limitations. We also examine the recent success of aptasensor technology and how
these findings pave the way for the analysis of small molecules in POCT and other health-related
applications. Finally, the current major limitations of aptamers are discussed, and possible approaches
for overcoming these challenges are presented.
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1. Introduction
Aptamers, which are short nucleic acid sequences, were described in 1990 for the first time and
proposed to be a promising alternative to antibodies [1,2]. In the following years, aptamers were
extensively tested and established in a variety of applications. Yet, after all these years, only a handful
of aptamers are commercially used (and approved) in diagnostics and therapeutics. As for the latter,
the most prominent therapeutic aptamer is Macugen by Pfizer, which was approved by the FDA in
2004, for treating neovascular age-related macular degeneration (AMD) [3]. Additional anti-angiogenic
aptamers for AMD treatment (Zimura, Fovista and Pegnivacogin) are currently in advanced stages of
clinical trials [4,5], along with a few more aptamers for other renal diseases [6]. Aptamers are widely
developed and successfully applied for numerous diagnostic applications and yet their translation
into commercial use in general and point-of-care testing (POCT) is still in its infancy. In this review,
we provide a thorough overview on the potential of aptamers for flexible diagnostics. We highlight the
challenges in the use of aptamers for diagnostics in general and POCT applications. We chose to focus
on small-molecule health markers, as their detection by conventional antibody-based approaches can
be limited due to a couple of factors.
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2. Small Molecule Targets
Small molecules, which are characterized by a low molecular weight (<900 Daltons) are organic
compounds which may regulate biological processes [7]. There are naturally occurring low molecular
weight compounds such as food-contaminants. Many of these contaminants are produced by
filamentous fungi and exhibit a wide range of potential harmful effects on health. The most abundant
and critical mycotoxins for human health are aflatoxins (produced by the Aspergillus species), ochratoxins
(produced by Penicillium and Aspergillus species) and Fusarium toxins (produced by over 50 species
of Fusarium) [8,9]. Alongside these naturally occurring compounds, many small molecules are
anthropogenic. Among these are polychlorinated biphenyls (PCBs), which have been widely used
in industrial applications. In the 1980s, the use of PCBs was mostly banned in all countries, since
the compounds exhibit moderate toxic potential in animals and humans and cannot be degraded
naturally [10,11]. There are also small molecules which act as pesticides and are used in agriculture.
In this context the most prominent compound is Glyphosate which was extensively discussed in the
media over the past year due to its potential carcinogenic effects [12,13].
Many pharmaceuticals are defined as small molecules. For drug application this could be
extremely attractive, since small molecules can pass the blood–brain barrier due to their size [14–16].
Modern medicine is unimaginable without pharmaceuticals and they are used all around the world.
They are ubiquitous and can also be found in the environment as a pollutant through human excretion.
The most analyzed pharmaceuticals in the environment are antibiotics, followed by analgesics and
hormones. In 713 analyzed water samples originating from all around the world, 631 were found to
contain these pharmaceutical compounds [16]. Moreover, small molecules often play important roles
in regulatory pathways in the human body. Vitamins, hormones, messenger molecules and cofactors
are different groups of small molecules which regulate the metabolism.
The ever-growing interest in monitoring these compounds in the environment—as well as in
the human body—led to a rising interest in the development of a variety of sensors for the detection
of small molecules. Due to their ubiquitous nature and important functions, small-molecule targets
are of high interest and extensive research has been carried out in this area in the past years. In the
last ten years, 17,912 research articles dealing with small molecules were published (Web of Science,
keyword “small molecules”, 07/31/20). Commonly, small molecules are detected via chromatographic
techniques, such as high-pressure liquid chromatography (HPLC) and gas chromatography (GC).
However, these methods are often expensive, require trained technicians and are time consuming.
A promising alternative for detection and monitoring of small molecules is the use of biosensors.
3. Biosensors
Biosensors are bioanalytical devices containing a biological element (such as, cells, antibodies,
enzymes or oligonucleotides [17]) which selectively reacts/binds with the target of interest. The resulting
biological recognition events are converted into a measurable signal by the transducer. The first
use of a biosensor, reported by Clark and Lyons in 1962, was for the detection and quantitation of
glucose concentration in blood [18]. Glucose oxidase was immobilized on a semi-permeable membrane,
which encased an oxygen electrode, and a decrease in the measured oxygen concentration oxygen
concentration was directly correlated to the glucose concentration [18].





In optical transduction methods, recognition binding events are converted into measurable changes
in various optical properties, such as fluorescence, refractive index and diffraction. Piezoelectric
transducers are based on changes of the molecular weight upon target binding. Since enzyme catalyzed
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reactions are usually exothermic, these changes in heat can be monitored by calorimetric transducers.
Finally, electrochemical transducers, such as the mentioned Clarke-biosensor, induce changes of current,
impedance or ion concentrations [19].
4. Aptasensors
In 1990, three laboratories independently announced the establishment of a new in vitro selection
method for nucleic acid sequences which bind their target in a highly selective manner. This technique,
termed as SELEX (systematic evolution of ligands by exponential enrichment), resulted in the discovery
of aptamers [1,2]. During the SELEX process, a library of random oligonucleotide sequences with
up to 1018 individual nucleic acid sequences is exposed to the desired target. A small percentage of
the library’s sequences binds to the target and subsequently separates. The latter are amplified via
polymerase chain reaction (PCR) and the selection process is typically repeated for 8–15 rounds [20].
To increase selectivity, counter selection may be performed (addition of molecular structures similar
to the target) and the sequences binding to the non-target structures are removed. Due to their
stringent selection process, aptamers offer a feasible alternative to antibodies and they offer several
prominent advantages. Aptamers are chemically synthesized at high reproducibility and low cost
compared to antibodies and they are stable over a wide range of temperature and pH, as well as in
organic solvents [20–22]. These significant advantages, along with their small size and the ease of their
immobilization and regeneration, have led to extensive research on aptamer-based biosensors [23].
The latter are termed aptasensors and the oligonucleic acid is commonly immobilized on the biosensor
surface. Immobilization drastically improves handling of the biosensor and the nucleic acid can be
regenerated more easily [24]. It is possible to design competitive assays through the application of
complementary strands, which bind the aptamer, offering new possibilities for biosensing in general
and small molecules in particular. The oligonucleotide nature of aptamers and complementary
strands offer the possibility to implement amplification and improve aptasensor sensitivity. Figure 1
schematically illustrates four typical modes of action of aptasensors: Sandwich or sandwich-like mode,
target-induced structure switching mode, target-induced dissociation mode and finally competitive
replacement mode [25].
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Figure 1. Overview of the different possible operational modes of aptasensors. (A) Sandwich or
sandwich-like mode: One aptamer is immobilized on a surface and the target molecule is added.
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Upon addition, the aptamer-target complex is formed. Afterwards, another labeled aptamer against the
respective target is introduced which binds to a different epitope of the target molecule. Transduction
is carried out via the labeled aptamer. (B) Target-induced structure switching (TISS) mode: The labeled
aptamer is immobilized on a surface. In this example, a fluorescence molecule is linked to the aptamer
and brought near a quenching surface. Upon target addition, the aptamer structure changes and the
fluorescence molecule is no longer quenched. In this case, transduction is carried out via fluorescence
measurement. (C) Target-induced dissociation (TID) mode: A complementary, labeled oligonucleotide
hybridizes with the immobilized aptamer. Upon target addition, the aptamer-target complex is
formed and the oligonucleotide is displaced. After washing steps, the respective signal decreases and
transduction can be carried out. (D) Competitive replacement (CR) mode: In this example, the target
molecule is immobilized on the surface. The labeled aptamer is added and forms the aptamer-target
complex. When the target molecule is added in excess, the aptamer preferably binds to the free molecule
and is removed from the immobilized target molecule. This change can then be monitored.
4.1. Sandwich or Sandwich-Like Mode
Similar to the concept of enzyme-linked immunosorbent (ELISA) assays, sandwich-like detection
methods have been established for aptamers. The oligonucleotide is immobilized on a surface and
binds its target, where a second aptamer binds a different binding site of the target to form a “sandwich”
structure (Figure 1A). This mode can be realized with two aptamers directed against different epitopes
of the target or in mixed approaches using an aptamer and an antibody. Therefore, it is possible to
create aptamer-target-antibody hybrids. Such hybrid-systems were successfully demonstrated to detect
cardiovascular biomarkers, such as troponin, but were not yet tested with small molecules [26,27].
The small molecule progesterone could also be detected in a sandwich-like lateral flow assay with
a final LOD of 5 nM using gold-immobilized aptamers [28]. Small molecules do not offer many
structural recognition elements which consequently limit the applicability of the sandwich-like strategy.
Moreover, due to the small size of the target, steric hinderance between the two binding aptamers
is likely to happen. Yet, it should be noted that when antibodies are employed this difficulty may
intensify due to their larger size and limited flexibility when binding epitopes.
4.2. Target-Induced Structure Switching (TISS) Mode
Target-induced structure switching (TISS) mode uses the aptamer’s ability to fold into a defined
3D-structure upon target binding. When the target molecule is introduced, the aptamer undergoes
structural rearrangements, as illustrated in Figure 1B. The aptasensor could be designed to either
measure changes in size of the aptamer upon target binding, the position of binding moieties or
structural stability. However, when detecting small molecules these structural changes can be marginal
and challenging to be implemented. Yet, many TISS mode aptasensor for the detection of small
molecules are described in literature and several examples are listed in Table 1. Several aptasensors for
the detection of ATP using the TISS mode were described in literature and were successfully tested in
aptamer binding buffer [29–31]. Moreover, extensive research was carried out for cocaine aptasensors
which were able to detect up to pM cocaine concentrations in serum [32].
4.3. Target-Induced Dissociation (TID) Mode
Like the sandwich-like and TISS modes, the target-induced displacement of complementary
oligonucleotides approach (TID), illustrated in Figure 1C, also relies on the structural properties of
the aptamer. However, the change of the aptamer conformation is not monitored directly, but the
displacement of a complementary oligonucleotide is detected. This oligonucleotide is usually designed
to bind in the aptamer-target binding site or in a place, where drastic structural changes occur upon
target binding. Upon target binding, the complementary oligonucleotide is displaced, which enables
the detection of this signal change for transduction (Figure 1C). Usually, the aptamer is immobilized on
the biosensor surface and the oligonucleotide is added. For transduction purposes, the complementary
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oligonucleotide can be modified at its 5’ or 3’-terminus. One possible modification is the addition
of a Cy5 or Cy3 molecule to monitor the change in fluorescence intensity upon target addition.
This would represent an optical aptasensor. Lee et al. demonstrated the ability of a TID-based
AU-NP aptasensor to monitor the small molecule hydroyvitamin D3 (25(OH)D3) in the micromolar
range [33]. These findings could be verified and further extended by the introduction of Cy5-labelled
complementary oligonucleotides [34].
4.4. Competitive Replacement (CR) Mode
In the competitive replacement mode, free target molecule competes with immobilized target
molecule. Since binding of the free target molecule is preferred, the labelled aptamer is not able to
bind to the immobilized target in the presence of the target (Figure 1D). A competitive aptasensor for
the detection of chloramphenicol (CHL) could be developed based upon this principle which was
able to detect CHL with a LOD of 451 pM. CHL was immobilized on a surface and biotin-labelled
CHL-aptamer was introduced. When no free CHL was available, the CHL-aptamer bound the
immobilized CHL and transduction was performed via streptavidin-modified gold nanoparticles
(AuNPs). However, when free CHL was available the CHL-aptamer formed a complex with it
and no sandwich-like structure on the surface could be formed [35]. Another aptasensor with the
competitive replacement mode could be tested successfully for the detection of the small molecule
neomycin B. In this setup, the target antibiotic is immobilized on a surface and then bound by the
aptamer. Upon addition of higher neomycin B concentrations, the aptamer is displaced and binds
to the free neomycin B. This change is then transduced with faradaic impedance spectroscopy (FIS).
This aptasensor was capable of measuring the small molecule with a LOD in the µM range [36].
Another competitive aptasensor for the detection of the small molecule aflatoxin B1 (AFB1) could be
developed. The anti-AFB1-aptamer was fused with the anti-thrombin-aptamer. The aptasensor surface
was coated with immobilized AFB1. When no free AFB1 was present, the aptamer-fusion-complex was
able to bind to the sensor surface. The anti-thrombin-aptamer then captured thrombin which cleaves
a peptide substrate. This cleavage was then used as the transduction method. However, when free
AFB1 is present, the aptamer-fusion-complex does not bind to the immobilized AFB1 and the substrate
cannot be cleaved by thrombin after washing steps. The aptasensor was able to detect the mycotoxin
with a LOD of 0.5 nM [37].
4.5. Applicability of the Different Aptasensor Modes for the Detection of Small Molecules
We compiled a table with a selection of aptasensors for the detection of small molecules with their
respective operational modes such as competitive replacement (CR) mode, TISS, TID and sandwich-like
mode. For the selection please see Table 1. It is evident that the majority of the presented aptasensors
operate with the target induced structure switching mode, followed by competitive replacement and
target-induced dissociation. The least used operational mode is the sandwich-like mode. This could be
due to the necessity of having two aptamers directed against two different epitopes of the target analyte.
Small molecules offer limited structural motifs for detection purposes and therefore complicate the
design of sandwich-like assays even more. The second least used operational mode is the target induced
dissociation mode when operating aptasensors. The use of TID requires structural knowledge of the
used aptamer to identify either the target binding site or areas of strong structural changes. Only with
this knowledge or “trial-and-error” it is possible to design the complementary oligonucleotides so
that they are displaced upon target binding. In contrast to the TID mode no in-depth knowledge
of the aptamer structure is needed for the TISS mode to operate successfully. The only requirement
for a successful TISS mode is a significant structural change of the aptamer upon target binding.
When this is not the case, the TID mode offers an effective alternative. When the displacement of the
complementary oligonucleotide cannot be monitored with the transduction method, it is possible to
label the oligonucleotide and amplify the transduction process, e.g., for mass-sensitive transduction
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methods. Another option to amplify transduction processes is the use of a variety of nanomaterials
which also enable higher signal-to-noise ratios (SNR).
Table 1. Selection of aptasensors against a variety of small molecules with their operational modes,
limits of detection (LOD) and sample composition.
Target Mode LOD Sample Composition Reference
Aflatoxin B1 TISS pM Beer/Wine [38]
Aflatoxin B1 CR nM Buffer [37]
Aflatoxin M1 TISS nM Spiked milk [29]
Aflatoxin M1 CR nM Buffer [30]
ATP TISS nM Buffer [39]
ATP TISS µM Buffer [31]
ATP TISS µM Buffer [40]
Ochratoxin A TID nM Buffer [41]
Ochratoxin A TID nM Grape juice/serum [42]
Chloramphenicol CR pM Serum/milk [35]
Cocaine TISS pM Serum [32]
Cocaine TISS nM Buffer [43]
Cocaine TISS nM Buffer [44]
Estradiol TISS fM Buffer [45]
Neomycin B CR µM Buffer [36]
Progesterone Sandwich nM Buffer [28]
25-Hydroxyvitamin D3 TID µM Serum [33]
4.6. Integration of Nanomaterials
In recent years, nanotechnology was embedded in a variety of aptasensors to improve sensitivity
and SNR. Nanomaterials can be incorporated in two manners: Nanoparticles as signalling elements and
nanostructured surfaces as transducers or amplificators. For the former, aptasensors which incorporate
gold nanoparticles (AuNPs) and quantum dots (QDs) were reported with promising sensitivity and
signal amplification [46,47]. AuNP-based biosensors often operate with an optical transduction method
since the aggregation of the nanoparticles upon aptamer-target binding leads to a wavelength shift
from 520 nm to 650 nm. Assays can be designed in a sandwich-like mode with two aptamers against
the respective target. These two aptamers are then immobilized on the AU-NP-surface and the AuNPs
aggregate upon target addition, which leads to a wavelength shift [48]. Since AuNPs have quenching
properties they are suitable for fluorometric aptasensors. Electrochemical transduction methods in
AuNP-based aptasensors have also been reported. The large surface area and high redox activity of
the gold nanoparticles lead to signal enhancement and increased biosensor sensitivity [46].
Semiconducting nanocrystals, also called quantum dots, are another nanomaterial capable of
significantly improving biosensing sensitivity and signal amplitude. In recent studies, QDs were
functionalized with aptamers. A quencher-labelled complementary oligonucleotide was added which
binds to the aptamer when no target is present. Upon target binding, the oligonucleotide dissociates
and the fluorescence signal increases [49].
Another promising nanomaterial for the development of aptasensors is porous silicon (PSi) [50,51].
The latter is a nanostructured porous material with unique optical properties and a large surface area,
allowing for a greater number of aptamers to be immobilized. Most PSi-based aptasensors are optical,
in which binding of the target molecules to the immobilized aptamers induce changes in the reflectivity
of the porous transducer owing to changes in the average refractive index.
Such aptasensors were successfully demonstrated for label-free detection of various targets [52–54].
Nanostructured graphene materials, such as graphene oxide (GO), are another class of promising
candidates for aptasensor surfaces. These materials offer excellent quenching properties. Additionally,
single-stranded DNA (ssDNA) is easily adsorbed on the surface of the material and drastically improves
the handling and generation of modified sensor surfaces [46]. Aptamer-coated GO surfaces were
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already successfully tested to detect the mycotoxin B1 in complex matrices such as beer or wine.
The aptasensor operated in a TISS mode and exhibited a LOD of 0.05 ng·mL−1 [38]. A label-free
approach for the femtomolar detection of the hormone 17β-estradiol with aptamer-coated GO surfaces
could also be demonstrated [45]. The working principle of this TISS mode aptasensor is shown in
Figure 2. Another novel aptasensing approach is the use of molecularly imprinted polymers (MIP)
alongside aptamers to detect target molecules in an extremely sensitive matter. MIP are artificial
recognition units which can be specifically tailored to detect certain compounds. Moreover, MIP are
extremely stable and can be produced cheaply. By integrating aptamers and MIP, new diagnostic
tools can be developed which combine both benefits in one device. Such hybrid-MIP approach was
used to design an aptasensor for tetracycline which was able to detect the antibiotic with a LOD of
144 fM. The major advantage of this aptasensor was its stability. After storing the sensor for four
weeks at ambient conditions, no drastic change in signal intensity upon biosensing could be monitored.
Moreover, the hybrid-MIP could be used several times with consecutive denaturation and regeneration
steps [55]. This biosensor illustrates one of the main advantages of aptasensors, since they can be used
several times and can be regenerated easily. Antibodies are susceptible to permanent denaturation
and are therefore heavily impacted by the solution in which the biosensor operates. In aptasensors,
these problems do not arise [56].
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a series of previous chemical modifications are necessary. Firstly, a glassy carbon electrode (GCE)
is modified with a graphene oxide (GO) layer. The GO diazonium salts are then electroche ically
reduced hich leads to the E / E hybrid surface. The -groups on the E surface are
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In general, aptasensors offer a range of advantages co pared to antibody-based biosensors.
o ever, the already established and clinically proven i unoassays are difficult to co pete ith
and oreover, existing aptasensors were only extensively tested for a small range of targets and usually
in non-clinical environments (for example buffer). In the ever-growing field of medical diagnostics,
aptasensors could fill an important gap between expensive and rather difficult to handle immunoassays
and point of care (POCT) diagnostics. To fill this gap however, existing aptamers need to be optimized
for monitoring these small molecules with an adequate sensitivity and selectivity. It could be shown that
the sensitivity could be drastically improved when nanomaterials were incorporated in the aptasensor.
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5. Comparison of Aptasensors and Immunosensors for Small Molecule Sensing
In the previous chapters we gave an overview of the possible operational modes of aptasensors
and optimization possibilities using a variety of nanomaterials. Over the past decade, aptasensors were
extensively used and optimized. This resulted in the construction of aptasensors which are superior
to the well-established antibodies in terms of limit of detections. We compiled a table of these small
molecule targets and compared the LOD of aptasensors with the LOD of immunosensors for these
targets. The resulting Table 2 is shown below.
Table 2. Selection of superior aptasensors for the detection of small molecules compared with the most
efficient immunosensor alternative based on limit of detection (LOD) values.
Target LODAptasensor LODImmunosensor Ref.Aptasensor Ref.Immunosensor
Tetracycline 5 pM 13 pM [57] [58]
Cocaine 100 pM 0.49 nM [59] [60]
Bisphenol A 1 pM 9 pM [61] [62]
Ochratoxin A 0.3 pM 5 pM [63] [64]
Estradiol 1 fM 55 fM [65] [66]
For the small molecules tetracycline, bisphenol A, ochratoxin A and estradiol the LODs of
aptasensors and immunosensors are comparably low and enable sensitive biosensing possibilities.
However, it is notable that the aptasensor for the detection of cocaine is superior (100 pM LOD) to
the respective immunosensor (0.49 nM). To highlight the flexibility and possibilities of aptasensor
development we describe the major accomplishments in cocaine aptasensing in the past years.
This progress is notable, since this picomolar LOD was only achieved with a variety of aptasensor
improvements over the past years. In 2006, the first aptasensor for cocaine detection was developed
based on the target-induced structure switching (TISS) operational mode. The aptasensor exhibited
a LOD of 10 µM which was too high for clinical applications [67]. This aptasensor was optimized
using a different operational mode in 2009. In this biosensing approach, the sandwich-mode was used.
Moreover, the cocaine-aptamer was split in two fragments, where one fragment was immobilized on the
biosensor surface and the other one was labeled and freely available in solution. Upon cocaine addition,
the equilibrium was shifted from the two separated aptamer fragments to the aptamer-target-complex
and electrochemical transduction was carried out. This aptasensor was able to detect cocaine with a
LOD of 1 µM [68]. The split-aptamer approach was extensively explored by other groups and refined
using nanomaterials such as quantum dots (QD) and a variety of nanoparticles such as PtNPs and
AuNPs [59,69,70]. In 2015, a nanocomposite aptasensor for the detection of cocaine was able to detect
the compound with a final LOD of 100 pM. In this aptasensor, the aptamer is linked to AuNPs which
are attached to a nanocomposite modified glassy carbon (GC) electrode. When no cocaine is present
and the aptamer is partially unfolded, ferricyanide is brought close to the electrode surface. However,
when cocaine is present, the negatively charged AuNPs approach the electrode surface, which results
in inhibited electron transfer and the redox probe current decreases [59]. Even the most recent
immunosensor for cocaine biosensing (0.49 nM [60]) is not able to compete with the LOD of 100 pM
exhibited by the presented aptasensor. This drastic improvement of LOD over the past years highlights
the high versatility of aptasensing technology. Once an aptamer against a certain target is selected,
the biosensor design can be optimized to drastically improve the aptasensor performance. The different
operational modes such as TID, TISS and Sandwich-like and the incorporation of nanomaterials offer
optimization options to increase sensitivity. Of course, it is also possible to optimize immunosensors
with nanomaterials and different operational modes. However, one major limiting factor in sensitivity
is the immobilization density of the capture probe on the biosensor surface. Since the aptamer is
drastically smaller than an antibody, higher immobilization densities are possible, leading to higher
sensor efficiencies. The majority of targets shown in Table 2 are environmental contaminants, whereas
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Estradiol is the only small molecule relevant in health monitoring. In the following chapter we examine
the recent advances in aptasensor technology for the detection of small molecules in health monitoring.
6. Current Status of Aptasensors for the Detection of Small Molecules in Health Monitoring
In recent years, due to increasing interest in small molecules, aptamers directed against these
molecules were selected via SELEX. Since 2015, 1196 research articles or reviews have been written
including the keyword “aptasensor” (Web of Science, 07/31/20). Moreover, a lot of these articles not only
describe the selection process via SELEX, but also the development of an aptasensor for the detection
of the selected target molecule. To give a brief overview of the currently available aptamers against
important health markers, we used the “Richtlinie der Bundesärztekammer zur Qualitätssicherung”
(guideline of the German medical association to maintain quality standards) (Rili-Bäk). This is a
guideline for German laboratories to maintain quality standards. Major chemical industries such as
Roche Diagnostics acknowledge this guideline and use it for their own POCT products. Based on the
table in the Rili-Bäk with all relevant existing health markers, we removed analytes which are not
defined as small molecules (<900 kDa) from the resulting table and checked whether an aptamer for
the desired target was reported in literature. The resulting analytes and their indications as health
markers are shown in Table 3.
As shown in Table 3, aptamers for many important hormones, which are analyzed in laboratory
tests, are available in literature. Additionally, an aptamer for the detection of 25-hydroxyvitamin D3
is described in literature, which is another significant health marker since Vitamin D deficiency is a
widespread illness. No aptamers were reported for aldosterone, bilirubin, uric acid and creatinine yet.
In summary, the development of aptamers for targeting small molecules in health monitoring was
mainly driven by the selection of aptamers against hormones. In addition, aptamers against other
relevant small molecules such as cortisol and 25(OH)D3 were also selected. As hormones are clinically
tested mostly by radioimmunometric methods which are costly and time extensive, these available
aptamers offer the potential to develop aptasensors for point-of-care testing. However, with the use of
aptasensors, some challenges arise both in general limitations of aptamers and in aptamer selection
processes. In the following, we examine the major challenges in the detection of small molecules using
aptasensors and how to solve those problems to make aptamers more attractive for POCT applications.
Table 3. Selection of relevant small molecules measured in health monitoring. The current state-of-art
testing method is mentioned, as well as whether an aptamer against the analyte is available or not.





Aldosterone Hypertension Radioimmunometric N - -
Bilirubin Hyperbilirubinemia Colorimetric N - -
Cortisol Hypercortisolism/Hypocortisolism Radioimmunometric Y 2017 [71]
Creatinine Kidney health Fluorometric/Colorimetric N - -
Estradiol Hormonal illnesses in women ELISA Y 2007 [72]
Progesterone Wide range of indications Radioimmunometric Y 2015 [73]
Testosterone Wide range of indications Radioimmunometric Y 2017 [74]
Uric acid Hyperuricemia/Hypouricemia Fluorometric/Colorimetric N - -
25(OH)D3 Vitamin D deficiency HPLC Y 2017 [33]
7. Challenges in the Detection of Small Molecules Using Aptasensors
Small molecules are one of the most extensively studied aptamer targets in literature. For example,
the ATP aptamer was extensively studied in literature and thousands of articles were published using
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this aptamer. However, in the last 10 years only a handful of new aptamers against small molecules
for health monitoring (besides the previously mentioned hormones) were selected and published.
In this subsection we explore both, general limitations when using aptamers for the detection of small
molecules and more specialized challenges which can occur in the selection process.
7.1. General Challenges
One of the major limitations of aptamers for the detection of small molecules is due to the small
size of the target molecule. It was reported that the target molecular weight is proportional to the
binding affinity of the aptamer in most cases [75,76]. This can be explained by the rather limited
presence of functional groups in small molecules. These functional groups, however, are important for
specific target recognition and target binding. In the theophylline binding aptamer it could be shown
that hydrogen bonds are extremely important target recognition and binding [77]. Consequently, fewer
functional groups lead to decreased specificity and binding affinity. This poses a problem for the
development of new aptamers for small molecules since the target analytes are usually monitored
in the nanomolar range (regarding health markers) and require high specificity. Patents for a variety
of aptamer applications also significantly inhibited innovation processes so that researches did not
decide to invest time and material in the discovery of new aptamers for small molecules [78].
7.2. SELEX-Related Challenges
One main advantage of aptamers is the high degree of selectivity when the selection process
(SELEX) is carried out optimally. This includes a sufficient amount of selections rounds (10–15) and
counter selection rounds. Another important step in the SELEX process is the separation of the
target-bound aptamer from the unbound oligonucleotides. Therefore, the target molecule is often
immobilized on a surface. For protein targets, hydrophobic interactions with the surface may be
sufficient for separation. For cell targets, centrifugation or fluorescence activated cell sorting (FACS)
is used. When immobilizing small molecules however, these targets often lack functional groups
needed for conjugation chemistry and therefore immobilization. Moreover, introduction of functional
groups is problematic and alters the structure of the small molecule which could lead to false-positive
binding. Additionally, aptamers of the selection library could falsely bind to the linker molecule.
Moreover, introducing new functional groups is time consuming. The alternative, using the already
existing functional groups further decreases the number of functional groups available for aptamer
target recognition. Counter-selection steps should be carried out in SELEX to increase specificity and
exclude cross-reactivity [79,80]. However, in an already time-consuming protocol these extra steps
may drastically worsen the economics. Since the discovery of the SELEX process in 1990, a variety
of new SELEX methods were reported in literature. For an overview of the existing SELEX methods,
and their context in the use for the selection of small molecule aptamers, see Figure 3. The capillary
electrophoresis (CE) SELEX and Nitrocellulose SELEX were successfully tested for the selection of
new aptamers against proteins such as IgE and rhVEGF165 [81,82]. These new approaches offered
faster selection rounds and a higher heterogeneity of the selection pools. However, both SELEX
techniques are not suitable for the selection of small molecule aptamers since the target molecule
needs to exhibit a certain size to be excluded in the separation steps. Microfluidic systems were also
reported which incorporate magnetic-bead-based SELEX, CE-SELEX and Sol-Gel SELEX methods.
These systems suffer from the lack of real-time monitoring of the aptamer enrichment. This results in
more time-extensive selection processes and consequently higher experimental costs. Moreover, higher
failure rates and selection blindness are reported. These circumstances make these methods (currently)
not suitable for the selection of aptamers in the POCT context. A promising new method, called
electrochemical SELEX could be successfully used to select and aptamer against the small molecule
11-Deoxycortisol. In this approach, the target molecule is immobilized on a gold electrode surface.
Then, the interaction between the selection library and the target molecule can be monitored in real-time
via voltammetric measurements. Compared with the conventional SELEX method, no labelling of
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the oligonucleotides is necessary [83]. Another promising SELEX method is the capture SELEX.
Compared to the previously mentioned methods such as CE-SELEX, Sol-Gel SELEX and the classic
SELEX, in this method the oligonucleotides are immobilized. Since the immobilization of small
molecules inherits a variety of problems, immobilization of the oligonucleotide is usually preferred
and drastically improve the selection process [84]. Moreover, the use of capture SELEX automatically
leads to complimentary oligonucleotides. This facilitates the development of an aptasensor in TID
mode since the complementary strand of ssDNA can be used directly in this aptasensor.
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7.3. Challenges regarding Kd Determination
When new aptamers are selected via SELEX, an important classification number for characterization
is the dissociation constant (Kd). The lower the Kd the higher the affinity of the aptamer to the
respective target. There are a variety of methods to measure Kd such as spectroscopy based methods,
mass-sensitive methods and separation-based methods [85]. To determine the Kd either the aptamer
or the target molecule is titrated against the other molecule. Since the aptamers are usually larger
than the small molecule, this leads to low signal-to-noise ratios and binding events are difficult
to detect. Kd determination methods can be classified in two groups: Immobilization of one
binding partner (either aptamer or target) or immobilization-free methods. Immobilization-based
methods include plasmon resonance (SPR), where one partner is immobilized and the Kd is measured.
Immobilization-free methods include isothermal calorimetry (ITC), capillary electrophoresis (CE)
and microscale thermophoresis (MST) [86]. Different methods were used to determine the Kd of
the aptamer directed against the small molecule ochratoxine A (OTA). The results indicated a wide
range of determined Kd, ranging from 125 to 374 nM. The previously reported literature value of
the OTA-binding aptamer was 200 nM [87]. High variability of experimentally detected dissociation
constants shows one of the major problems in Kd determination. Since the Kd is an important
classification factor for further aptasensor development, this could lead to a range of problems.
However, this discrepancy between Kd measuring methods could also be due to their fundamentally
different working methods. In one approach, the target or aptamer is immobilized, in the other method
both binding partners are free in solution. Therefore, the Kd method should be chosen with the aptamer
application in mind. For aptasensor approaches, where the aptamer is usually immobilized, methods
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such as SPR should be chosen to generate reliable Kd results. However, when looking for therapeutic
aptamers for example, immobilization-free Kd determination methods such as ITC, MST or CE should
be used. To approximate the factual Kd, different methods (either immobilization-free or not) should
be used, and a high number of replicates should be carried out. In recent years, a couple of promising
new determination methods were reported. Isothermal Titration Calorimetry (ITC), which belongs to
the calorimetric and label-free methods, was used successfully in the determination of Kd of aptamers
against small molecules such as 25(OH)D3 and cocaine [33,88]. ITC offers fast results with a label-free
experimental setup. However, high aptamer or target concentrations are needed to perform the ITC,
therefore often resulting in costly experiments [89]. Another promising candidate for Kd determination
is MicroScale Thermophoresis (MST). MST is based on the thermophoretic mobility of molecules in
temperature gradients. The mobility of the molecule heavily depends on its size, hydration shell and
charge, therefore when the aptamer-target complex is formed, a change in movement behavior can be
monitored. This leads to the dissociation constant Kd. Strong structural changes are needed to occur in
the aptamer upon target binding to observe the Kd in the MST. The Kd determination of small molecule
aptamers using MST could be shown in the 17β-estradiol-binding aptamer and the well-established
ATP-aptamer. Additionally, the MST was carried out successfully for the characterization of the
ochratoxin A-binding aptamer [90–92]. The main advantage of the MST is the low sample volume,
fast generation of results and easy experimental layouts. The major downside is the need for labelled
interaction partners. Usually the aptamer is fluorescently labelled, whereas it is also possible to label
the target molecule. The labelling is usually carried out during chemical synthesis of the aptamer.
As already mentioned, modifications and labels could alter the binding properties (and consequently
the Kd) and should be evaluated carefully. Automated microchip electrophoresis could be shown to be
another promising method in Kd determination since it requires low reagent use and leads to fast Kd
results [15].
8. Aptamers in Point-of-Care Testing (POCT)
Point-of-care testing (POCT) is defined by the ability to instantly monitor health markers on-site
(for example directly at the hospital) and get results quickly. The current workflow in the detection of
health-markers is to take the biological sample at the hospital, send it to a central laboratory (when the
hospital has no own laboratory) and get the results in a couple of days. However, this approach suffers
from a couple of disadvantages. Firstly, experienced personnel are needed to analyze the biological
sample in the laboratory, secondly, costly equipment is needed and finally, the samples need to be
shipped to the testing facility. In the POCT approach, the biological samples are taken and analyzed at
the same location. This is possible with simple-to-handle medical devices and rather cheap resources
which are needed for the tests. When POCT is established, the health markers can be measured
quickly, cheaply and without the need for experienced personnel. Moreover, it is possible to create a
network of POCT institutions and continuously exchange data and experience. This would lead to a
decentralized approach of health monitoring and would offer fast and reliable results for the customer,
anywhere. However, the transition from the current approach to a POCT-approach is difficult. At the
beginning of a POCT-transitional phase, the hospital suffers from extra effort and expense. Employees
need to be trained to handle the POCT-devices, a central data point and managing software needs to
be established and a solid quality management system needs to be established. The POCT should
be a complementary approach to the central-laboratory, with the same quality-management and
reproducibility. The resulting data needs to be comparable to the results of the central laboratories of
the current approach. All these challenges need to be taken in account when an institution transitions
from the current “central laboratory approach” to the POCT-approach. Aptasensor-based POCT
incorporates all advantages of aptamers including long-term stability, aptamer regeneration and high
sensitivity in the nanomolar range. In contrast to antibodies, aptamers in POCT devices could be
more durable, cheaper and could withstand harsher environments, which could simplify prior sample
preparation. Aptamers could especially excel in the detection of small molecules, which usually
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regulate important functions in the body and are relevant as health markers. One disadvantage
of aptamers is their susceptibility to nucleases. However, this vulnerability to nucleases could be
negligible attributable to the POCT approach. Firstly, measurements in POCT ideally should be carried
out in a short period of time (e.g., 10 min), which limits the influence of nuclease activity. Secondly,
the aptamers in POCT approaches will not be regenerated most of the time. In case they should
be regenerated, it is possible to introduce aptamer modification to make the oligonucleotide more
nuclease-resistant such as 3’-poly-dA tails or 3’-biotin caps for in vitro measurements [93,94]. Finally,
aptamer immobilization itself makes the aptamers less prone for DNase activity. POCT systems should
be easy to handle, cheap and fast. With the use of aptasensors as a base for new POCT systems,
the first two mentioned points could be successfully established. The time aspect, however, needs
to be evaluated thoroughly. Aptamer-target binding is a time-dependent step (until equilibrium is
reached) with a potential optimum for POCT application. However, this spot needs to be evaluated
carefully, since a too short incubation time may lead to insufficient binding and therefore unreliable
results with low signal-to-noise ratios. This problem gets even worse when small molecules are used
which lead to low signal-to-noise ratios by themselves. When designing aptasensor-based POCT
applications, the incubation time is a crucial parameter which needs to be optimized previously—both
for applicability and quality assurance. In the worst case, the desired sensitivity of the established
aptasensor will not get used to its fullest extent.
A promising platform for POCT applications is the smartphone-assisted sensor. In 2020,
4.78 billion people on earth owned a smart and feature phone which makes smartphone-based
POCT an extremely feasible approach which also enables at-home-testing of biological markers.
In 2016, a smartphone-assisted aptasensor was reported. The sensor system consists of an optical
waveguide, which guides the light from the smartphone through a SPR sensor to the output coupler.
Then, the wavelength shift of the SPR is monitored. Upon target addition, the aptamer-target complex
is formed and the wavelength shift is monitored. This smartphone-assisted sensor was successfully
used for the detection of the C-reactive protein with a LOD of 12.46 nM (normal C-reactive protein
(CRP) concentration in blood is 40 nM) [95]. The working principle of the sensor is shown in Figure 4.
The working principle of this sandwich-like aptasensor is shown in Figure 3. The use of smartphones
in POCT extends the idea of POCT so that self-testing of various health markers at home could be
possible in the future. The only part which needs to be purchased in order to measure these analytes
is the rather cheap polymer-based SPR sensor, while readout can be performed using the users own
smartphone [96].
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9. Conclusions and Future Prospects
In point-of-care testing, aptamers offer a wide range of advantages compared to antibodies
when used as the biosensing platform. Aptamers have a long shelf-life and are more stable in
rougher chemical conditions. Moreover, they can be produced in bulk in a much cheaper way than
antibodies. Aptamers are especially suitable for the detection of small molecules since their small size
results in large binding capacities when the aptamer is immobilized on the sensor surface. This is
an advantage for the detection of small molecules, since more target analyte can be bound by the
aptamer and transduced. Another advantage of aptamers for the detection of small molecules is
their potential high specifity and a variety of different operational modes such as sandwich-like, TISS,
TID and competitive mode. These modes make the biosensor development extremely flexible and
new sensing approaches can be introduced easily. In POCT-systems aptamers pave the way for fast
and efficient test kits such as lateral-flow assays or SPR-based biosensors with the incorporation of
smartphones. However, the selection and characterization of aptamers for small molecules is the major
bottleneck for the discovery of new aptamers against small molecules. The size of small molecules
such as testosterone or other hormones leads to a variety of problems in the selection process and
Kd determination. Problems include limited chemical groups needed for immobilization both in Kd
determination and SELEX. Moreover, aptamers need to be selected more stringent, with more selection
rounds, counter selection rounds and overhauled SELEX methods such as the electrochemical SELEX
technique which makes nucleotide-labeling needless. Another bottleneck of aptasensing in the POCT
area are inconsistent Kd determination methods. There are a variety of methods to determine the
dissociation constant of an aptamer, however there are large deviations of the reported Kd between
these methods. When characterizing aptamers for the POCT use, different measurement approaches
should be used, and multiple measurements are necessary. Methods such as microscale thermophoresis
and isothermal titration calorimetry are two of the most efficient Kd determination methods since the
aptamer-target-complex is formed freely in solution and no immobilization is needed. Aptasensors for
the detection of small molecules also need to leave proof-of-principle experiments behind and explore
the real testing conditions. See Table 1 for a selection of recently reported aptasensor for the detection
of small molecules. The majority of these aptasensors were tested in buffer systems and have not
been tested for rather complex clinical samples such as human serum or environmental samples yet.
These complex matrices confront the aptamer with a series of potential problems: Extremely low target
concentration, cross-reactivity, other potential contaminants and nucleases. This environment could
lead to low signal-to-noise ratios. An efficient starting point of SNR improvement is the optimization
of the transduction method. Nanomaterials such as porous silicon (PSi), graphene oxide (GO) and
gold nanoparticles (AuNPs) are recent advances in this field with immense potential for aptasensor
improvement. These materials offer both efficient signal amplification methods and an aptamer
immobilization surface which drastically improves the handling of the aptasensor. These possibilities
and recent advances could lead to a dramatic increase in aptasensor research interest. Cocaine
immunosensing is a good example which shows the potential of aptasensors in the current research
environment. The first cocaine aptasensor was published in 2006 with moderate results. Since then,
the sensor was drastically improved which led to an LOD increase of five-fold and successful biosensing
serum in the femtomolar concentration range [32]. Until now, no superior antibody immunosensor
could be developed for cocaine sensing and the aptasensor remains one of the most effective sensing
approaches [97]. While aptasensors might still be in an early development state in the context of POCT,
this example clearly demonstrates the high potential of aptasensors as well as the manifold options for
their development and optimization.
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